↓ Skip to main content

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer

Overview of attention for article published in New England Journal of Medicine, September 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#7 of 20,599)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Readers on

mendeley
336 Mendeley
citeulike
2 CiteULike
Title
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
Published in
New England Journal of Medicine, September 2016
DOI 10.1056/nejmoa1606220
Pubmed ID
Authors

Hamdy, Freddie C., Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, Malcolm Mason, Chris Metcalfe, Peter Holding, Michael Davis, Tim J. Peters, Emma L. Turner, Richard M. Martin, Jon Oxley, Mary Robinson, John Staffurth, Eleanor Walsh, Prasad Bollina, James Catto, Andrew Doble, Alan Doherty, David Gillatt, Roger Kockelbergh, Howard Kynaston, Alan Paul, Philip Powell, Stephen Prescott, Derek J. Rosario, Edward Rowe, David E. Neal, Hamdy, Freddie C, Donovan, Jenny L, Lane, J Athene, Mason, Malcolm, Metcalfe, Chris, Holding, Peter, Davis, Michael, Peters, Tim J, Turner, Emma L, Martin, Richard M, Oxley, Jon, Robinson, Mary, Staffurth, John, Walsh, Eleanor, Bollina, Prasad, Catto, James, Doble, Andrew, Doherty, Alan, Gillatt, David, Kockelbergh, Roger, Kynaston, Howard, Paul, Alan, Powell, Philip, Prescott, Stephen, Rosario, Derek J, Rowe, Edward, Neal, David E, , , Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE, ProtecT Study Group, Donovan, Jenny L., Lane, J. Athene, Peters, Tim J., Turner, Emma L., Martin, Richard M., Rosario, Derek J., Neal, David E.

Abstract

Background The comparative effectiveness of treatments for prostate cancer that is detected by prostate-specific antigen (PSA) testing remains uncertain. Methods We compared active monitoring, radical prostatectomy, and external-beam radiotherapy for the treatment of clinically localized prostate cancer. Between 1999 and 2009, a total of 82,429 men 50 to 69 years of age received a PSA test; 2664 received a diagnosis of localized prostate cancer, and 1643 agreed to undergo randomization to active monitoring (545 men), surgery (553), or radiotherapy (545). The primary outcome was prostate-cancer mortality at a median of 10 years of follow-up. Secondary outcomes included the rates of disease progression, metastases, and all-cause deaths. Results There were 17 prostate-cancer-specific deaths overall: 8 in the active-monitoring group (1.5 deaths per 1000 person-years; 95% confidence interval [CI], 0.7 to 3.0), 5 in the surgery group (0.9 per 1000 person-years; 95% CI, 0.4 to 2.2), and 4 in the radiotherapy group (0.7 per 1000 person-years; 95% CI, 0.3 to 2.0); the difference among the groups was not significant (P=0.48 for the overall comparison). In addition, no significant difference was seen among the groups in the number of deaths from any cause (169 deaths overall; P=0.87 for the comparison among the three groups). Metastases developed in more men in the active-monitoring group (33 men; 6.3 events per 1000 person-years; 95% CI, 4.5 to 8.8) than in the surgery group (13 men; 2.4 per 1000 person-years; 95% CI, 1.4 to 4.2) or the radiotherapy group (16 men; 3.0 per 1000 person-years; 95% CI, 1.9 to 4.9) (P=0.004 for the overall comparison). Higher rates of disease progression were seen in the active-monitoring group (112 men; 22.9 events per 1000 person-years; 95% CI, 19.0 to 27.5) than in the surgery group (46 men; 8.9 events per 1000 person-years; 95% CI, 6.7 to 11.9) or the radiotherapy group (46 men; 9.0 events per 1000 person-years; 95% CI, 6.7 to 12.0) (P<0.001 for the overall comparison). Conclusions At a median of 10 years, prostate-cancer-specific mortality was low irrespective of the treatment assigned, with no significant difference among treatments. Surgery and radiotherapy were associated with lower incidences of disease progression and metastases than was active monitoring. (Funded by the National Institute for Health Research; Current Controlled Trials number, ISRCTN20141297 ; ClinicalTrials.gov number, NCT02044172 .).

Twitter Demographics

The data shown below were collected from the profiles of 641 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 336 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 12 4%
Spain 3 <1%
Germany 2 <1%
Australia 2 <1%
Brazil 2 <1%
United Kingdom 2 <1%
Chile 1 <1%
France 1 <1%
Zimbabwe 1 <1%
Other 6 2%
Unknown 304 90%

Demographic breakdown

Readers by professional status Count As %
Researcher 67 20%
Other 46 14%
Student > Ph. D. Student 38 11%
Student > Bachelor 34 10%
Student > Postgraduate 33 10%
Other 118 35%
Readers by discipline Count As %
Medicine and Dentistry 231 69%
Unspecified 29 9%
Agricultural and Biological Sciences 25 7%
Biochemistry, Genetics and Molecular Biology 9 3%
Physics and Astronomy 8 2%
Other 34 10%

Attention Score in Context

This research output has an Altmetric Attention Score of 2611. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 November 2017.
All research outputs
#173
of 8,655,412 outputs
Outputs from New England Journal of Medicine
#7
of 20,599 outputs
Outputs of similar age
#7
of 253,705 outputs
Outputs of similar age from New England Journal of Medicine
#1
of 313 outputs
Altmetric has tracked 8,655,412 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 20,599 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 50.9. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 253,705 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 313 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.